Creative Biolabs is a world leader in the development of ELISA based kits and offers a wide range of assay kits for specific detection of disease-related proteins. Electrochemiluminescence (ECL) is a type of luminescence that occurs during electrochemical reactions in solutions. Methods based on enzyme labels have been developed for chemiluminescent immunoassays in Creative Biolabs. Our professional team is optimized to help you with high-quality and cost-effective testing service to make your project a success.
In electrochemiluminescence, electrochemically generated intermediates undergo a high degree of exergonic reaction to produce an electronically excited state and then emits light when relaxed to a lower energy level. This wavelength of emitted photons corresponds to the energy gap between these two states. ECL excitation can be caused by the high energy electron transfer (redox) reaction of the electro-generated material. This luminescent excitation is a form of chemiluminescence in which one/all of the reactants are electrochemically produced on the electrode.
ECL is typically observed during the application of potential to an electrochemical cell electrode in a solution of an aprotic organic solvent (ECL composition) containing a solution of a luminescent material (metal complex, polyaromatic hydrocarbon, nanoparticle, or quantum dot). In organic solvents, the oxidized and reduced forms of the luminescent material can be produced simultaneously on different electrodes, or on a single electrode by scanning the potential between oxidation and reduction. Excitation energy is obtained from the recombination of oxidized and reduced species.
Fig.1 The principle of electrochemiluminescence.1
Creative Biolabs has been devoted for the development of highly sensitive, more flexible, quantitative, and easy-to-use electrochemiluminescence immunoassays-based kits. ECL proved to be very useful in analytical applications as a highly sensitive and selective method. ECL provides a wider dynamic range, higher sensitivity, reduced matrix effects, and requires lower sample volumes, which allows for a broader assay.
The importance of electrochemiluminescence techniques detection for bio-related applications has been well established. ECLIA is heavily used commercially for many clinical lab applications. To assist customers for specific detection of disease-related proteins, Creative Biolabs provides a variety of ELISA based assay kits. If you are interested in our chemiluminescent immunoassay based kits development, please feel free to contact us for more details.
1. A Novel Highly Sensitive and Throughput Electrochemiluminescent Immunoassay System
Fig.2 The detection precision of the ECLIA system.2,4
This study developed an electrochemiluminescence immunoassay (ECLIA) system to meet the demand for high-accuracy, fast clinical testing. By incorporating magnetic separation modules, introducing a photomultiplier tube (PMT), and optimizing system timing, the system enhanced detection accuracy, sensitivity, and throughput. The magnetic separation improved accuracy, the PMT boosted sensitivity, and the timing optimization maximized test output. Finally, this study evaluated the overall performance of the ECLIA system which demonstrated excellent performance in linearity, signal-to-noise ratio, detection limit, reproducibility, and accuracy. Overall, this optimized ECLIA system offers high-throughput, sensitive, and reliable detection, facilitating its potential clinical application.
2. A Novel Electrochemiluminescence Immunoassay for Measuring IgM-Free AIM
Fig.3 Specificity evaluation of the ECLIA for IgM-free AIM.3,4
In this work, researchers developed a specific antibody targeting IgM-free apoptosis inhibitor of macrophage (AIM) and established a fully automated, high-throughput electrochemiluminescence immunoassay (ECLIA) to quantify IgM-free AIM. The method was applied to assess the role of IgM-free AIM in diagnosing NASH-associated hepatocellular carcinoma (NASH-HCC) and viral HCC. Using ECLIA, they measured IgM-free AIM levels in 212 serum samples from patients with HCC related to NASH, hepatitis B, and hepatitis C. Additionally, they developed an ECLIA for total AIM (IgM-free and IgM-bound) and used size-exclusion chromatography to explore AIM's forms in the blood. This new ECLIA approach could enhance clinical studies on AIM and support HCC diagnosis.
References
For Research Use Only.